Akebia Therapeutics (AKBA) Debt to Equity: 2018-2025
Historic Debt to Equity for Akebia Therapeutics (AKBA) over the last 6 years, with Sep 2025 value amounting to $1.15.
- Akebia Therapeutics' Debt to Equity rose 250.52% to $1.15 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.15, marking a year-over-year increase of 250.52%. This contributed to the annual value of -$0.79 for FY2024, which is 30.63% up from last year.
- As of Q3 2025, Akebia Therapeutics' Debt to Equity stood at $1.15, which was down 28.87% from $1.61 recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Debt to Equity registered a high of $12.63 during Q4 2022, and its lowest value of -$2.63 during Q1 2023.
- Over the past 3 years, Akebia Therapeutics' median Debt to Equity value was -$1.08 (recorded in 2023), while the average stood at -$0.51.
- Per our database at Business Quant, Akebia Therapeutics' Debt to Equity spiked by 859.43% in 2022 and then tumbled by 2,442.19% in 2023.
- Akebia Therapeutics' Debt to Equity (Quarterly) stood at $1.32 in 2021, then skyrocketed by 858.60% to $12.63 in 2022, then crashed by 108.98% to -$1.13 in 2023, then surged by 30.63% to -$0.79 in 2024, then spiked by 250.52% to $1.15 in 2025.
- Its Debt to Equity was $1.15 in Q3 2025, compared to $1.61 in Q2 2025 and $1.89 in Q1 2025.